- Q3 sales grew 14% YoY to $283.7M, led by a 26% increase in international sales.
- Net loss reduced significantly to -$7.1M (-$0.10/share) vs. -$21.2M (-$0.31/share) YoY.
- Adjusted EBITDA improved to $18.0M (6% margin) compared to $2.8M (1% margin) in Q3 2025.
Why is $TNDM moving today? · SEC 8-K archive
$TNDM SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $TNDM: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $TNDM filing catalyst
Why did $TNDM trigger an AI stock catalyst alert?
$TNDM triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +4.5/10). Headline: Tandem Diabetes Q3 Sales Rise 14% to $283.7M, Net Loss Shrinks to $0.10/Share. Key points: - Q3 sales grew 14% YoY to $283.7M, led by a 26% increase in international sales. - Net loss reduced significantly to -$7.1M (-$0.10/share) vs. -$21.2M (-$0.31/share) YoY. - Adjusted EBITDA improved to $18.0M (6% margin) compared to $2.8M (1% margin) in Q3 2025.
How did $TNDM stock react after the SEC filing?
After the SEC 8-K for $TNDM, observed market reaction: T0 price $17.99. Past moves do not guarantee future results.
Where can I get real-time $TNDM SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $TNDM via Telegram and the VIP Web Terminal from €10/month.